Contemporary cancer chemotherapy need to be active against malignant cell (selectivity), to be based on the molecular biology of the cancer cell, to enhance immune response to cancer, and to stop development of resistance to drug. Research in this field is expensive, as well as the cost of newly discovered drugs. Targeted therapies are registered in the Republic of Serbia and their applications are controlled by the state authority. At the Oncology Institute of Vojvodina smaller number of patients was treated with targeted therapy than with classical chemotherapy. However, our costs for treating patients with monoclonal therapies are at the level of those worldwide.
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً